Share-based Payment Arrangement, Expense of Aligos Therapeutics, Inc. from 30 Sep 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aligos Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2019 to 31 Dec 2025.
  • Aligos Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $1,457,000, a 15% decline year-over-year.
  • Aligos Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $5,044,000, a 40% decline year-over-year.
  • Aligos Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $5,044,000, a 40% decline from 2024.
  • Aligos Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $8,452,000, a 33% decline from 2023.
  • Aligos Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $12,652,000, a 14% decline from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Aligos Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $5,044,000 $1,457,000 -$248,000 -15% 01 Oct 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
Q3 2025 $5,292,000 $1,467,000 -$576,000 -28% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $5,868,000 $1,161,000 -$895,000 -44% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $6,763,000 $959,000 -$1,689,000 -64% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $8,452,000 $1,705,000 -$877,000 -34% 01 Oct 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
Q3 2024 $9,329,000 $2,043,000 -$1,166,000 -36% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $10,495,000 $2,056,000 -$1,141,000 -36% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $11,636,000 $2,648,000 -$1,016,000 -28% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $12,652,000 $2,582,000 -$840,000 -25% 01 Oct 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
Q3 2023 $13,492,000 $3,209,000 -$282,000 -8.1% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $13,774,000 $3,197,000 -$797,000 -20% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $14,571,000 $3,664,000 -$122,000 -3.2% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $14,693,000 $3,422,000 -$239,000 -6.5% 01 Oct 2022 31 Dec 2022 10-K 09 Mar 2023 2022 FY
Q3 2022 $14,932,000 $3,491,000 -$101,000 -2.8% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $15,033,000 $3,994,000 +$546,000 +16% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $14,487,000 $3,786,000 +$1,030,000 +37% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $13,457,000 $3,661,000 +$2,360,000 +181% 01 Oct 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q3 2021 $11,097,000 $3,592,000 +$2,576,000 +254% 01 Jul 2021 30 Sep 2021 10-Q 02 Nov 2022 2022 Q3
Q2 2021 $8,521,000 $3,448,000 +$3,121,000 +954% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $5,400,000 $2,756,000 +$2,425,000 +733% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $2,975,000 $1,301,000 01 Oct 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
Q3 2020 $1,016,000 +$865,000 +573% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $327,000 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $331,000 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q3 2019 $151,000 01 Jul 2019 30 Sep 2019 10-Q 25 Nov 2020 2020 Q3

Aligos Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $5,044,000 -$3,408,000 -40% 01 Jan 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
2024 $8,452,000 -$4,200,000 -33% 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
2023 $12,652,000 -$2,041,000 -14% 01 Jan 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
2022 $14,693,000 +$1,236,000 +9.2% 01 Jan 2022 31 Dec 2022 10-K 09 Mar 2023 2022 FY
2021 $13,457,000 +$10,482,000 +352% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
2020 $2,975,000 +$2,223,000 +296% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
2019 $752,000 01 Jan 2019 31 Dec 2019 10-K 23 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.